EFFICACY AND SAFETY OF UPADACITINIB IN A CHINESE SUBGROUP OF PATIENTS WITH RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS
机构：[1]Peking Union Medical CollegeHospital (PUMCH), Chinese Academy of Medical Sciences, Rheumatology,Beijing, China[2]National Clinical Research Center for Dermatologic andImmunologic Diseases (NCRC-DID), Key Laboratory of Rheumatology &Clinical Immunology, Beijing, China[3]West China Hospital, Sichuan University,Rheumatology, Chengdu, China四川大学华西医院[4]Pingxiang People’s Hospital, Rheumatology,Pingxiang, China[5]Zhuzhou Hospital Affiliated to Xiangya School of Medicine,Rheumatology, Zhuzhou, China[6]First Affiliated Hospital of Baotou MedicalCollege, Rheumatology, Baotou, China[7]Shanghai Changhai Hospital,Rheumatology and Immunology, Shanghai, China[8]People’s Hospital ofXinjiang Uygur Autonomous Region, Rheumatology, Urumqi, China[9]FirstAffiliated Hospital of Shantou University Medical College, Rheumatology,Shantou, China[10]First Affiliated Hospital of Bengbu Medical College,Rheumatology, Bengbu, China[11]First Affiliated Hospital of Kunming MedicalUniversity, Rheumatology, Kunming, China[12]AbbVie Deutschland GmbH &Co. KG, Immunology, Ludwigshafen, Germany[13]AbbVie Inc, Immunology,Illinois, United States of America[14]AbbVie China, Immunology, Shanghai,China
第一作者机构：[1]Peking Union Medical CollegeHospital (PUMCH), Chinese Academy of Medical Sciences, Rheumatology,Beijing, China[2]National Clinical Research Center for Dermatologic andImmunologic Diseases (NCRC-DID), Key Laboratory of Rheumatology &Clinical Immunology, Beijing, China
通讯机构：[11]First Affiliated Hospital of Kunming MedicalUniversity, Rheumatology, Kunming, China
推荐引用方式(GB/T 7714)：
Zeng X.,Liu Y.,Hu J.,et al.EFFICACY AND SAFETY OF UPADACITINIB IN A CHINESE SUBGROUP OF PATIENTS WITH RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS[J].ANNALS OF THE RHEUMATIC DISEASES.2022,81:1324-1324.doi:10.1136/annrheumdis-2022-eular.1119.
APA：
Zeng, X.,Liu, Y.,Hu, J.,Li, J.,Wang, Y....&Liang, P..(2022).EFFICACY AND SAFETY OF UPADACITINIB IN A CHINESE SUBGROUP OF PATIENTS WITH RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS.ANNALS OF THE RHEUMATIC DISEASES,81,
MLA：
Zeng, X.,et al."EFFICACY AND SAFETY OF UPADACITINIB IN A CHINESE SUBGROUP OF PATIENTS WITH RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS".ANNALS OF THE RHEUMATIC DISEASES 81.(2022):1324-1324
医学